Artificial Intelligence

New study shows an AI platform matches expert radiologists in tumor measurement, promising a new era of precision and consistency in breast cancer surgery.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Syntax Data launches Saidee, an AI that builds custom portfolios using proprietary, traceable data, aiming to solve key compliance fears for financial advisors.

As Singapore mandates e-invoicing, Cygnet.One leverages its global platform to simplify complex digital tax compliance for multinational enterprises.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

Ad-tech giant Teads reports massive revenue growth post-merger, but a $352M impairment and restructuring signal deep integration challenges.

With $266M and 300MW of secured power, HighBrook Investors is tackling Northern Virginia's data center shortage, signaling a major PE shift.

Following key acquisitions, the AI firm pivots to a vertically integrated defense powerhouse, forecasting explosive growth backed by a swelling order backlog.

The deal merges Bonterra’s enterprise grantmaking with Deed’s modern employee engagement platform, signaling a major shift in corporate social responsibility.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

A new report finds AI boosts elite team productivity 4x, but warns that automating mid-level tasks could create a critical cybersecurity skills gap.

With $15M from top UAE families, TruDoc is scaling its 'hospital-at-home' model, signaling a major shift in how the GCC delivers critical care.